DR. KAMBIZ THOMAS MOAZED, MD
Medical Practice at Broadway, New York, NY

5993407, Nov 30, 1999

Oct 25, 1996

8/736902

Kambiz Thomas Moazed - New York NY

A61M 500

604 8

A temporary transnasal lacrimal insert is used in a surgical procedure for improving drainage from a patient's lacrimal sac to his or her nasal cavity. The insert includes a tubular member with a proximal end and an enlarged distal end. The insert also includes an attachment element about which ends of a tube can be fastened. In the procedure, a hole is created extending from the lacrimal sac into the nasal cavity using surgical techniques or a laser probe. Then, opposite ends of a tube are introduced through the patient's upper and lower puncta, through the patient's upper and lower canaliculi, through the lacrimal sac, through the hole, and into the nasal cavity. The ends of the tube are then threaded through the passage in the insert. The insert is then placed from the nasal cavity into the hole by forcing the proximal end of the insert through the hole and into the lacrimal sac, and abutting the enlarged distal end, which is larger than the hole, against a surface in the nasal cavity surrounding the hole. The ends of the tube are then fastened to the attachment element of the insert.

2002003, Mar 14, 2002

May 22, 2001

09/862744

Kambiz Moazed - New York NY, US

A61M005/00

604/008000

A temporary transnasal lacrimal insert is used in a surgical procedure for improving drainage from a patient's lacrimal sac to his or her nasal cavity. The insert includes a tubular member with a proximal end and an enlarged distal end. The insert also includes an attachment element about which ends of a silastic tube can be fastened. In the procedure, a hole is created extending from the lacrimal sac into the nasal cavity using surgical techniques or a laser probe. Then, opposite ends of a silastic tube are introduced through the patient's upper and lower puncta, through the patient's upper and lower canaliculi, through the lacrimal sac, through the hole, and into the nasal cavity. The ends of the silastic tube are then threaded through the passage in the insert. The insert is then placed from the nasal cavity into the hole by forcing the proximal end of the insert through the hole and into the lacrimal sac, and abutting the enlarged distal end, which is larger than the hole, against a surface in the nasal cavity surrounding the hole. The ends of the silastic tube are then fastened to the attachment element of the insert. Excess tube extending into the nasal cavity is then cut short to reduce nasal irritation. After the hole has sufficiently healed in about 3-6 months, the silastic tube and the insert are removed.

2003013, Jul 10, 2003

Feb 25, 2003

10/373508

Kambiz Moazed - New York NY, US

A61M005/00

604/008000

A temporary transnasal lacrimal insert is used in a surgical procedure for improving drainage from a patient's lacrimal sac to his or her nasal cavity. The insert includes a tubular member with a proximal end and an enlarged distal end. The insert also includes an attachment element about which ends of a silastic tube can be fastened. In the procedure, a hole is created extending from the lacrimal sac into the nasal cavity using surgical techniques or a laser probe. Then, opposite ends of a silastic tube are introduced through the patient's upper and lower puncta, through the patient's upper and lower canaliculi, through the lacrimal sac, through the hole, and into the nasal cavity. The ends of the silastic tube are then threaded through the passage in the insert. The insert is then placed from the nasal cavity into the hole by forcing the proximal end of the insert through the hole and into the lacrimal sac, and abutting the enlarged distal end, which is larger than the hole, against a surface in the nasal cavity surrounding the hole. The ends of the silastic tube are then fastened to the attachment element of the insert. Excess tube extending into the nasal cavity is then cut short to reduce nasal irritation. After the hole has sufficiently healed in about 3-6 months, the silastic tube and the insert are removed.

2011028, Nov 17, 2011

Jan 29, 2010

13/138260

Kambiz Thomas Moazed - New York NY, US

A61K 31/05, A61K 31/13, A61K 31/138, A61K 31/541, A61K 31/136, A61K 31/4178, A61K 31/47, A61K 31/485, A61K 31/7105, A61K 39/08, A61K 31/191, A61K 36/62, A61K 31/655, A61P 27/06, A61P 35/00, A61K 31/352

4242391, 514731, 514456, 514733, 514662, 514651, 5142278, 514648, 514397, 514734, 514307, 514282, 514 44 A, 514455, 514557, 424778, 514150

Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a pigmented tissue related disease.

2012007, Mar 29, 2012

Jul 21, 2010

13/261047

Kambiz Thomas Moazed - New York NY, US

A61K 9/00, A61K 31/352, A61K 31/222, A61K 31/541, A61K 31/196, A61K 31/4178, A61K 31/472, A61K 31/485, A61K 31/13, A61K 31/713, A61K 38/16, A61K 36/185, A61K 31/23, A61K 31/557, A61K 31/655, A61K 31/136, C07F 3/06, A61P 27/02, A61P 43/00, A61P 27/06, A61P 35/00, A61K 31/05, B82Y 5/00

424427, 514731, 514733, 514456, 514546, 5142278, 514567, 514397, 514734, 514307, 514282, 514662, 514 44 A, 514 208, 514455, 424778, 514547, 514573, 514150, 514454, 514641, 556130, 977773, 977906

Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a pigmented tissue related disease.

2012020, Aug 16, 2012

Nov 30, 2011

13/373797

Kambiz Thomas Moazed - New York NY, US

A61K 9/00, A61K 39/08, A61K 33/26, A61K 33/24, A61K 31/7088, A61K 31/13, A61K 31/05, A61P 27/06, A61P 35/00, A61P 27/02, A61K 8/40, A61K 31/352, B82Y 5/00

424427, 424 62, 4242391, 424641, 424646, 424649, 514 44 A, 514454, 514662, 514731, 977773, 977906

Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are compositions for lightening or darkening the pigmented tissues or treating a pigmented tissue disease.